12:00 AM
May 14, 2012
 |  BC Week In Review  |  Company News  |  Other News

Abbott neurology news

Abbott will pay $1.5 billion to federal and state authorities to resolve criminal and civil liability regarding past marketing activities for neurology drug Depakote divalproex. Under the settlement, Abbott pleaded guilty to a misdemeanor violation for misbranding Depakote, which is approved in the U.S. to treat epileptic seizures and bipolar mania and to prevent migraines. The U.S. Department of Justice...

Read the full 280 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >